Conditional inactivation of HIF-1 using intrabodies

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Hypoxia, low oxygen, is common in solid tumors and promotes cancer cell survival.
• Hypoxia-Inducible Factor 1 (HIF-1) is a key regulator activated by hypoxia, linked to tumor aggressiveness and poor prognosis.
• HIF-1 is a potential therapeutic target for cancer treatment.

Purpose of the Study:

• To develop a novel therapeutic strategy targeting HIF-1.
• To investigate the efficacy of single-domain llama antibodies against HIF-1alpha.
• To assess the impact of HIF-1 inhibition on hypoxia-induced gene activation.

Main Methods:

• Developed single-domain llama antibodies targeting the HIF-1alpha oxygen-dependent degradation domain.
• Engineered conditional expression of these intrabodies in mammalian cells.
• Assessed the interference with pVHL binding and inhibition of hypoxia-induced target gene activation.

Main Results:

• Conditional expression of HIF intrabodies effectively inhibited hypoxia-induced activation of endogenous target genes.
• Intrabody expression interfered with the binding of HIF-1alpha to pVHL.
• Demonstrated the specificity and temporal control of protein inactivation using inducible intrabody targeting.

Conclusions:

• Single-domain llama antibodies provide a novel and specific approach for targeting HIF-1.
• Inducible intrabody targeting offers a precise strategy for temporal protein inactivation.
• This approach holds potential for the treatment of hypoxia-driven diseases, including cancer.